Birdwatch Note
2024-03-25 17:34:01 UTC - NOT_MISLEADING
Aucune étude sérieuse? Qui decide du sérieux d’une étude? Le fait qu’elle infirme/confirme votre avis? Simple: les avis, c’est dans les commentaires. L’HCQ est utilisée depuis des décennies très régulièrement par des millions de gens qui n’en mourraient pas, jusqu’au COVID. https://www.cdc.gov/malaria/resources/pdf/fsp/drugs_2017/Hydroxychloroquine_fr_2017.pdf
Written by DF9600215DBA373A238C07AAFC40FE7B6805A6010CA2A050A6C742ACFC06DB84
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1772277179180613876
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1772316017227702408
- noteId - 1772316017227702408
- participantId -
- noteAuthorParticipantId - DF9600215DBA373A238C07AAFC40FE7B6805A6010CA2A050A6C742ACFC06DB84 Participant Details
- createdAtMillis - 1711388041202
- tweetId - 1772277179180613876
- classification - NOT_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 0
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 1
- trustworthySources - 1
- summary
- Aucune étude sérieuse? Qui decide du sérieux d’une étude? Le fait qu’elle infirme/confirme votre avis? Simple: les avis, c’est dans les commentaires. L’HCQ est utilisée depuis des décennies très régulièrement par des millions de gens qui n’en mourraient pas, jusqu’au COVID. https://www.cdc.gov/malaria/resources/pdf/fsp/drugs_2017/Hydroxychloroquine_fr_2017.pdf
Note Status History
createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
2024-03-25 17:34:01 UTC (1711388041202) |
2024-03-25 20:20:17 UTC (1711398017784) |
CURRENTLY_RATED_NOT_HELPFUL | 2024-03-26 03:28:55 UTC (1711423735421) |
NEEDS_MORE_RATINGS | 2024-03-25 20:20:17 UTC (1711398017784) |
CURRENTLY_RATED_NOT_HELPFUL |
Note Ratings
rated at | rated by | |
2024-03-25 19:53:34 -0500 | Rating Details | |
2024-03-25 19:12:03 -0500 | Rating Details | |
2024-03-25 18:58:48 -0500 | Rating Details | |
2024-03-25 18:22:30 -0500 | Rating Details | |
2024-03-25 17:04:37 -0500 | Rating Details | |
2024-03-25 16:26:18 -0500 | Rating Details | |
2024-03-25 16:09:44 -0500 | Rating Details | |
2024-03-25 16:05:42 -0500 | Rating Details | |
2024-03-25 15:56:24 -0500 | Rating Details | |
2024-03-25 15:52:53 -0500 | Rating Details | |
2024-03-25 15:52:09 -0500 | Rating Details | |
2024-03-25 15:47:52 -0500 | Rating Details | |
2024-03-25 15:37:54 -0500 | Rating Details | |
2024-03-25 15:31:04 -0500 | Rating Details | |
2024-03-25 15:03:15 -0500 | Rating Details | |
2024-03-25 15:01:02 -0500 | Rating Details | |
2024-03-25 14:58:08 -0500 | Rating Details | |
2024-03-25 14:52:42 -0500 | Rating Details | |
2024-03-25 14:50:44 -0500 | Rating Details | |
2024-03-25 14:45:18 -0500 | Rating Details | |
2024-03-25 14:40:36 -0500 | Rating Details | |
2024-03-25 14:40:17 -0500 | Rating Details | |
2024-03-25 14:39:15 -0500 | Rating Details | |
2024-03-25 14:24:30 -0500 | Rating Details | |
2024-03-25 14:03:47 -0500 | Rating Details | |
2024-03-25 13:47:26 -0500 | Rating Details | |
2024-03-25 13:30:47 -0500 | Rating Details | |
2024-03-25 13:26:40 -0500 | Rating Details | |
2024-03-25 12:44:31 -0500 | Rating Details | |
2024-03-25 12:43:58 -0500 | Rating Details | |
2024-03-26 08:41:39 -0500 | Rating Details | |
2024-03-26 08:09:47 -0500 | Rating Details | |
2024-03-26 07:24:40 -0500 | Rating Details | |
2024-03-26 06:05:53 -0500 | Rating Details | |
2024-03-26 05:50:33 -0500 | Rating Details | |
2024-03-26 01:56:08 -0500 | Rating Details | |
2024-03-26 01:43:36 -0500 | Rating Details | |
2024-03-25 23:35:03 -0500 | Rating Details | |
2024-03-25 23:11:33 -0500 | Rating Details | |
2024-03-25 21:35:57 -0500 | Rating Details | |
2024-03-25 21:02:32 -0500 | Rating Details | |
2024-03-26 18:04:02 -0500 | Rating Details | |
2024-03-26 11:09:49 -0500 | Rating Details | |
2024-03-26 08:37:29 -0500 | Rating Details | |
2024-03-26 08:00:52 -0500 | Rating Details | |
2024-03-26 07:06:41 -0500 | Rating Details | |
2024-03-26 06:57:38 -0500 | Rating Details | |
2024-03-26 05:50:19 -0500 | Rating Details | |
2024-03-26 04:46:07 -0500 | Rating Details | |
2024-03-26 04:03:51 -0500 | Rating Details | |
2024-03-26 03:25:03 -0500 | Rating Details | |
2024-03-26 02:13:12 -0500 | Rating Details | |
2024-03-26 01:42:34 -0500 | Rating Details | |
2024-03-25 23:42:47 -0500 | Rating Details | |
2024-03-25 22:23:58 -0500 | Rating Details | |
2024-03-25 21:06:31 -0500 | Rating Details | |
2024-03-25 20:35:36 -0500 | Rating Details | |
2024-03-25 18:44:39 -0500 | Rating Details | |
2024-03-25 18:17:54 -0500 | Rating Details | |
2024-03-25 16:32:30 -0500 | Rating Details | |
2024-03-25 16:09:39 -0500 | Rating Details | |
2024-03-25 16:07:54 -0500 | Rating Details | |
2024-03-25 15:56:51 -0500 | Rating Details | |
2024-03-25 15:50:32 -0500 | Rating Details | |
2024-03-25 15:36:35 -0500 | Rating Details | |
2024-03-25 15:26:42 -0500 | Rating Details | |
2024-03-25 15:21:13 -0500 | Rating Details | |
2024-03-25 15:10:54 -0500 | Rating Details | |
2024-03-25 15:10:45 -0500 | Rating Details | |
2024-03-25 14:34:26 -0500 | Rating Details | |
2024-03-25 14:33:16 -0500 | Rating Details | |
2024-03-25 14:33:08 -0500 | Rating Details | |
2024-03-25 14:31:31 -0500 | Rating Details | |
2024-03-25 14:28:01 -0500 | Rating Details | |
2024-03-25 14:21:01 -0500 | Rating Details | |
2024-03-25 14:20:18 -0500 | Rating Details | |
2024-03-25 14:13:59 -0500 | Rating Details | |
2024-03-25 14:11:31 -0500 | Rating Details | |
2024-03-25 14:08:33 -0500 | Rating Details | |
2024-03-25 14:02:26 -0500 | Rating Details | |
2024-03-25 13:54:59 -0500 | Rating Details | |
2024-03-25 13:48:05 -0500 | Rating Details | |
2024-03-25 13:20:43 -0500 | Rating Details | |
2024-03-25 13:13:02 -0500 | Rating Details | |
2024-03-25 13:11:09 -0500 | Rating Details | |
2024-03-25 13:07:30 -0500 | Rating Details | |
2024-03-25 13:03:50 -0500 | Rating Details | |
2024-03-25 12:54:36 -0500 | Rating Details | |
2024-03-25 12:53:35 -0500 | Rating Details | |
2024-03-25 12:44:23 -0500 | Rating Details | |
2024-03-31 09:34:21 -0500 | Rating Details | |
2024-04-18 08:49:04 -0500 | Rating Details | |
2024-04-04 07:49:49 -0500 | Rating Details | |
2024-04-25 07:20:31 -0500 | Rating Details | |
2024-04-12 09:06:30 -0500 | Rating Details | |
2024-05-14 16:12:30 -0500 | Rating Details | |
2024-05-11 14:27:09 -0500 | Rating Details | |
2024-05-15 08:32:41 -0500 | Rating Details | |
2024-05-15 08:17:36 -0500 | Rating Details | |
2024-05-16 09:10:24 -0500 | Rating Details | |
2024-05-15 08:05:43 -0500 | Rating Details | |
2024-05-09 01:26:39 -0500 | Rating Details | |
2024-05-22 10:55:45 -0500 | Rating Details | |
2024-05-15 21:36:33 -0500 | Rating Details | |
2024-05-15 14:13:58 -0500 | Rating Details | |
2024-05-14 06:31:33 -0500 | Rating Details | |
2024-05-09 21:53:56 -0500 | Rating Details | |
2024-05-31 17:02:26 -0500 | Rating Details | |
2024-05-18 19:19:15 -0500 | Rating Details | |
2024-05-16 05:44:25 -0500 | Rating Details | |
2024-05-10 02:16:34 -0500 | Rating Details | |
2024-06-10 07:13:45 -0500 | Rating Details | |
2024-08-07 05:20:02 -0500 | Rating Details | |
2024-08-06 23:02:38 -0500 | Rating Details |